E
CRBU icon

Ergoteles’s Caribou Biosciences CRBU Stock Holding History

Ergoteles’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,500
Closed -$53.1K – 221
2023
Q2 		$53.1K Buy
+12,500
New +$56.2K ﹤0.01% 953
2022
Q1 		– Sell
-41,487
Closed -$626K – 1283
2021
Q4 		$626K Buy
+41,487
New +$807K 0.02% 558

Other funds holding CRBU

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ergoteles's CRBU Position: Q3 2023 in Review

Ergoteles sold out of Caribou Biosciences (CRBU) in Q3 2023, closing a stake of 12,500 shares — an estimated $53.1K sold.

Ergoteles first reported a position in CRBU in Q4 2021 and held it in 2 quarters. The position peaked at $626K in Q4 2021. 126 funds tracked by Wall St. Rank hold CRBU as of Q3 2023.

  • Ergoteles reported no remaining Caribou Biosciences position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 12,500 Caribou Biosciences shares in Q3 2023, an estimated $53.1K.
  • Ergoteles first reported a position in Caribou Biosciences in Q4 2021 and held it in 2 quarters.
  • Ergoteles's Caribou Biosciences position peaked at $626K in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.